A Pfizer Inc. spokeswoman said that by making the vaccine available for “all major circulating strains of the human papillomavirus (HPV),” the vaccine protects against 90 percent of all strains of the virus found in the United States.
Pfizer announced in February that it would begin clinical trials on the vaccine, which aims to target girls and women ages 9 to 11 years old.
A requirement for immunization—potentially including a flu shot for those who are on the Canadian border—will be tested during the 2019–20 school year, said Gary Shooshan, the chief public health officer for New Brunswick, in a press release issued by Pfizer.
“The positive outcome of this clinical trial will be utilized to determine whether it’s appropriate to offer HPV vaccine to all Grade 4 students in our province, as recommended by Health Canada and other provinces and territories,” Mr. Shooshan said.
The Canadian Vaccine Alliance, which advises provinces and territories on health-care matters, had supported the vaccine’s approval, as did the Alberta Ministry of Health.